Background: First studies have shown that juvenile psoriasis is associated with an increased prevalence of comorbidity. Objectives: We carried out a data analysis to characterise the profiles of comorbidity in children with psoriasis and atopic eczema. Methods: Prevalence data were derived from the database of a German statutory health insurance company according to ICD-10 codes L40 (psoriasis) and L20 (atopic eczema) of children up to 18 years insured in 2009. Results: Data sets included 1.64 million persons and 293,181 children. 1,313 children = 0.45% (0.42-0.47) had a diagnosis of psoriasis and 30,354 = 10.35% (10.24-10.47) had a diagnosis of atopic eczema. Obesity, hyperlipidaemia, arterial hypertension and diabetes were more often diagnosed in children with psoriasis in comparison to all children without psoriasis and to those with atopic eczema. Conclusion: Children with psoriasis and atopic eczema show different and specific patterns of comorbidity which should be detected early and treated adequately.

Keywords:
Atopic eczema, Children, Comorbidity, Epidemiology, Health care, Psoriasis
1.
Gudjonsson JE, Elder JT: Psoriasis: epidemiology. Clin Dermatol 2007;25:535-546.
2.
Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K: Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008;216:366-372.
3.
Altobelli E, Petrocelli R, Marziliano C, Fargnoli MC, Maccarone M, Chimenti S, Peris K: Family history of psoriasis and age at disease onset in Italian patients with psoriasis. Br J Dermatol 2007;156:1400-1401.
4.
Henseler T, Christophers E: Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-986.
5.
Fan X, Xiao FL, Yang S, Liu JB, Yan KL, Liang YH, Sun LD, Du WH, Jin YT, Zhang XJ: Childhood psoriasis: a study of 277 patients from China. J Eur Acad Dermatol Venereol 2007;21:762-765.
6.
Seyhan M, Coşkun BK, Sağlam H, Ozcan H, Karincaoğlu Y: Psoriasis in childhood and adolescence: evaluation of demographic and clinical features. Pediatr Int 2006;48:525-530.
7.
Kumar B, Jain R, Sandhu K, Kaur I, Handa S: Epidemiology of childhood psoriasis: a study of 419 patients from northern India. Int J Dermatol 2004;43:654-658.
8.
Nanda A, Kaur S, Kaur I, Kumar B: Childhood psoriasis: an epidemiologic survey of 112 patients. Pediatr Dermatol 1990;7:19-21.
9.
Raychaudhuri SP, Gross J: A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol 2000;17:174-178.
10.
Al-Mutairi N, Manchanda Y, Nour-Eldin O: Nail changes in childhood psoriasis: a study from Kuwait. Pediatr Dermatol 2007;24:7-10.
11.
Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I: Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010;162:633-636.
12.
Gelfand JM, Weinstein R, Porter SB, Neimann AL, Berlin JA, Margolis DJ: Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. Arch Dermatol 2005;141:1537-1541.
13.
Leung DYM: New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergol Int 2013;62:151-161.
14.
Proudfoot LE, Powell AM, Ayis S, Barbarot S, Baselga Torres E, Deleuran M, Fölster-Holst R, Gelmetti C, Hernández-Martin A, Middelkamp-Hup MA, Oranje AP, Logan K, Perkin M, Patrizi A, Rovatti G, Schofield O, Spuls P, Svensson Å, Vestergaard C, Wahlgren CF, Schmitt J, Flohr C; European Dermato-Epidemiology Network (EDEN): The European TREatment of severe Atopic eczema in children Taskforce (TREAT) survey. Br J Dermatol 2013;169:901-909.
15.
Guttman-Yassky E, Nograles K, Krueger J: Contrasting pathogenesis of atopic dermatitis and psoriasis - part I: clinical and pathologic concepts. J Allergy Clin Immunol 2011;127:1110-1118.
16.
Beikert FC, Langenbruch AK, Radtke MA, Kornek T, Purwins S, Augustin M: Willingness to pay and quality of life in patients with atopic dermatitis. Arch Dermatol Res 2013;306:279-286.
17.
Augustin M, Herberger K, Hintzen S, Heigel H, Franzke N, Schäfer I: Prevalence of skin lesions and need for treatment in a cohort of 90 880 workers. Br J Dermatol 2011;165:865-873.
18.
Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, Margolis DJ, Strom BL: The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007;143:1493-1499.
19.
Boehncke WH, Boehncke S, Tobin AM, Kirby B: The ‘psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011;20:303-307.
20.
Silverberg JI, Simpson EL: Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. Pediatr Allergy Immunol 2013;24:476-486.
21.
Spergel JM: From atopic dermatitis to asthma: the atopic march. Ann Allergy Asthma Immunol 2010;105:99-106; quiz 107-109, 117.
22.
Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, Hamid Q, Kapp A, Leung DY, Lipozencic J, Luger TA, Muraro A, Novak N, Platts-Mills TA, Rosenwasser L, Scheynius A, Simons FE, Spergel J, Turjanmaa K, Wahn U, Weidinger S, Werfel T, Zuberbier T; European Academy of Allergology; Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Group: Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Allergy 2006;61:969-987.
23.
Akdis CA: Allergy and hypersensitivity: mechanisms of allergic disease. Curr Opin Immunol 2006;18:718-726.
24.
Augustin M, Reich K, Glaeske G, Schaefer I, Radtke MA: Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 2010;90:147-151.
25.
Christophers E: Comorbidities in psoriasis. Clin Dermatol 2007;25:529-534.
26.
Pearce DJ, Morrison AE, Higgins KB, Crane MM, Balkrishnan R, Fleischer AB Jr, Feldman SR: The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat 2005;16:319-323.
27.
Mrowietz U, Elder JT, Barker J: The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006;298:309-319.
28.
Sterry W, Strober BE, Menter A; International Psoriasis Council: Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 2007;157:649-655.
29.
Gottlieb AB, Chun C, Dann F: Psoriasis comorbidities. J Dermatolog Treat 2008;19:5-21.
30.
Boehncke S, Thaci D, Beschmann H, Ludwig RJ, Ackermann H, Badenhoop K, Boehncke WH: Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007;157:1249-1251.
31.
Schön MP, Boehncke WH: Psoriasis - immunopathogenesis, genetics and therapeutic perspectives. N Engl J Med 2005;352:1899-1912.
32.
Jacobi A, Kupke C, Behzad M, Hertl M: Comorbidities, metabolic risk profile and health-related quality of life in German patients with plaque-type psoriasis: a cross-sectional prospective study. Int J Dermatol 2013;52:1081-1087.
33.
Ochsmann EB, Escobar Pinzón CL, Letzel S, Kraus T, Michaelis M, Muenster E: Prevalence of diagnosis and direct treatment costs of back disorders in 644,773 children and youths in Germany. BMC Musculoskelet Disord 2010;11:193.
34.
Franzke N, Montenbruck M, Langenbruch AK, Beikert FC, Kresken J, Augustin M: Drug supply for psoriasis - results from a national pharmacy network. J Dtsch Dermatol Ges 2013;11:638-643.
35.
Erler A, Beyer M, Muth C, Gerlach FM, Brennecke R: Garbage in - garbage out? Validity of coded diagnoses from GP claims records. Gesundheitswesen 2009;71:823-831.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.